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Abstract
Background: Based on the key role of hyperglycemia-mediated oxidative stress in the patho-
genesis of diabetic cardiomyopathy, increasing antioxidant defense would represent a novel 
therapeutic approach for management of diabetic cardiomyopathy. This study was designed to 
seek the effectiveness of chronic treatment with resveratrol, a potent natural antioxidant, on 
streptozotocin-nicotinamide experimental model of type 2 diabetic hearts.
Methods: Male rats randomized into four groups (n = 12): control, diabetic, control + res-
veratrol, and diabetic + resveratrol.
Results: Four-month oral resveratrol administration to diabetic rats (5 mg/kg/day) alleviated 
the reduction of cardiac antioxidant enzymes activities (3.88 ± 0.48 vs. 1.49 ± 0.43 U, p < 0.05  
for superoxide dismutase, and 2.72 ± 0.26 vs. 1.18 ± 0.19 nmol/min/mL, p < 0.05 for ca-
talase) and the enhancement of cardiac oxidative markers (5.01 ± 0.37 vs. 7.23 ± 0.51 ng,  
p < 0.05 for 8-isoprostane, 6.03 ± 0.87 vs. 8.49 ± 0.52 µmol, p < 0.05 for nitrite/nitrate, and 
0.44 ± 0.03 vs. 0.59 ± 0.04, p < 0.05 for oxidized/reduced glutathione ratio), nuclear factor 
kappa B activity (0.37 ± 0.09 vs. 0.60 ± 0.11, p < 0.05) and apoptosis rate (0.98 ± 0.28 vs. 
1.63 ± 0.16, p < 0.05). Moreover, it improved left ventricular developed pressure (72.46 ± 8.16  
vs. 52.01 ± 11.32 mm Hg, p < 0.05) and coronary flow (14.08 ± 1.09 vs. 11.75 ± 1.43 mL/ 
/min × g, p < 0.05).
Conclusions: These beneficial cardioprotective observations suggest that treatment with 
resveratrol can potentially delay or attenuate the progression of diabetes-related cardiac com-
plications. (Cardiol J 2014; 21, 1: 39–46)
Key words: type 2 diabetes, antioxidant, hyperglycemia, redox status,  
cardiomyopathy, resveratrol
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Introduction
Diabetic cardiomyopathy has been defined 
as diabetes-mediated ventricular dysfunction 
independent of any vascular disease and hyperten-
sion, manifesting initially by diastolic dysfunction, 
later by systolic dysfunction, and finally by heart 
failure [1]. Diabetic cardiomyopathy is a common 
problem in diabetic population as it is detectable 
even in approximately 60% of well-controlled type 
2 diabetic patients [1]. While several mechanisms 
have been discussed for onset and development 
of diabetic cardiomyopathy, it is believed that 
oxidative stress resulting from diabetes-mediated 
hyperglycemia, lipotoxicity and mitochondrial 
uncoupling play central roles in the pathogenesis 
of diabetic cardiomyopathy [2–4]. Oxidative stress, 
an imbalance between oxygen/nitrogen free ra-
dicals production and antioxidant defense, cause 
oxidation or glycation of lipids, proteins and DNA, 
and results in extracellular matrix change, small 
vessel disease, autonomic neuropathy and defects 
in cellular Ca2+ transport and contractile proteins. 
These complications, in turn, can result in cardiac 
hypertrophy, stiffness, fibrosis and apoptosis [1–3].
During recent years many investigations have 
been directed toward increasing antioxidant defense 
as a novel therapeutic approach against diabetes-re-
lated cardiovascular complications [1, 2]. It has been 
widely accepted that resveratrol, a natural polypheno-
lic phytoalexin found in grapes, berries and peanuts, 
not only exerts potent antioxidant, anti-inflammatory, 
anti-apoptotic and some other cardioprotective effects 
in diabetic subjects, but also ameliorates diabetes-
-mediated hyperglycemia through insulin-dependent 
and insulin-independent pathways [5].
While there are sufficient evidences to sup-
port the protective role of resveratrol in different 
forms of heart diseases, there are few publications 
on the effects of resveratrol on diabetic cardio-
myopathy and none of them have explored its 
long-term effects. For instance, it has been shown 
that resveratrol given at 7 and 15 days increased 
antioxidant proteins and reduced infarct size and 
apoptosis rate in diabetic rat heart [6, 7]. Another 
study has proven that treatment with resveratrol 
(2.5 mg/kg/day orally for 2 weeks) induced Glut-4 
translocation and glucose uptake in diabetic rat 
myocardium [8]. Apart from that, Zhang et al. 
[9]  have shown that treatment with resveratrol 
(20 mg/kg/day orally for 4 weeks) improves left 
ventricular (LV) diastolic relaxation by inhibiting 
oxidative/nitrosative stress. A very recent study 
has shown that 8 weeks treatment with resveratrol 
(2.5 mg/kg/day; IP) improves diabetic heart fun-
ction through reducing ventricular inflammation 
and remodeling [10]. In another recent study it 
has been shown that resveratrol given at 2.5 mg/ 
/kg/day orally for 4 weeks prevented from cardiac 
and vascular dysfunction in diabetic rats through 
its effect on redox balance [5].
Most of researches on antidiabetic effects of res-
veratrol have been performed on animals, cell lines and 
tissue extracts and because of few performed clinical 
trials, scientists are not yet certain about sufficient 
efficacy of resveratrol in humans. On the other hand, 
since duration of diabetes is crucial for manifestation 
of some structural and functional complications of 
diabetic cardiomyo pathy [1], the translation from 
animal studies to clinical trials needs further studies 
to clarify the particular effects of resveratrol.
Currently, resveratrol has become available 
in pill form as a dietary supplement and based on 
previous studies, it seems that prescription of res-
veratrol is useful, safe and well tolerated. Given the 
key role of oxidative stress in the pathogenesis of 
diabetic cardiomyopathy, we conducted the present 
study to evaluate the antioxidant effect of chronic 
resveratrol ingestion on oxidative stress, apoptosis 
rate and function of the heart in the experimental 
model of type 2 diabetic rats.
Methods
Experimental design
Male Sprague-Dawley rats (3 months old with 
300–330 g of body weight; Razi Institute, Tehran, 
Iran) were housed in standard cages (3 rats in 
each), at room temperature (22–25°C) with 12:12-h 
light/dark cycles and free access to food and water. 
Rats were randomly divided into four groups (12 in 
each): normal control (NC), diabetic control (DC), 
normal control treated with resveratrol (NTR), and 
diabetic treated with resveratrol (DTR). This study 
was designed in accordance with US National Insti-
tutes of Health (NIH publication, No. 86–23, revised 
1996) and ARRIVE guidelines for the care and use of 
animals approved by the Ethics Committee for the 
Use of Animals in Research at Ahvaz Jundishapur 
University of Medical Sciences [11]. Type 2 diabetes 
was induced by injection of streptozotocin (50 mg/ 
/kg; IP) dissolved in 0.1 M of citrate buffer 
(pH 4.5), 15 min after the prescription of nicotinamide 
(110 mg/kg; IP) in 12 h fasted rats [12, 13]. Citrate 
buffer was injected alone in control rats. After 48 h 
blood glucose levels were measured using glucome-
ter (Arkray, Kyoto, Japan) and the rats with blood 
glucose levels higher than 250 mg/dL were included 
to the protocol as diabetic rats [12]. All manipula-
tions were held in the morning.
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Resveratrol treatment (Cayman chem., Ann 
Arbor, MI, USA) was carried out orally in aqueous 
solution for 4 months [12]. The dosage (5 mg/kg) 
was regulated every week. An oral glucose tole-
rance test (OGTT) was performed 1 day before 
killing the rats. OGTT first sample was taken from 
overnight fasted rats. Other blood samples were 
taken at 30, 60, 90, and 120 min intervals after inta-
ke of glucose solution at a dosage of 2 g/kg of body 
weight. At the end of experimental period, fasted 
rats were anesthetized with pentobarbital sodium 
(35 mg/kg IP) and blood samples (3 mL per rat) were 
collected from retro-orbital sinus for determina-
tion of plasma insulin. After cervical decapitation, 
the hearts and pancreases were quickly removed. 
The hearts of 6 rats were used for evaluating 
functional parameters by Langendorff apparatus 
and the hearts of the other 6 rats were considered 
for determination of redox status, nuclear factor 
kappa B (NF-kB) activity and apoptosis rate. The 
pancreases were homogenized for determination 
of pancreatic insulin content.
Heart preparation
After anesthetization, the hearts were excised, 
placed in ice-cold saline, and rapidly hung by the 
aorta on the cannula of Langendorff apparatus, as 
we previously described [14]. A pressure-trans-
ducing catheter was placed through the cannula 
and aortic valve into the chamber of the LV, and 
pressure was acquired with a computer connected 
to the transducer (Power-Lab, AD Instruments, 
Australia). After 5 min stabilization period, end 
diastolic and developed pressures were measured, 
and coronary flow rate was obtained by collecting 
the coronary effluent for 1 min.
Quantification of NF-kB activity
Nuclear factor kappa B activity was determi-
ned using NF-kB p65 transcription factor assay 
kit (Cayman chem.) according to the procedures 
provided by the manufacturer. Briefly, 2 μg of 
cardiac nuclear extracts were incubated with an 
oligonucleotide containing the NF-kB consensus 
site, and then were incubated with monoclonal and 
secondary antibodies directed against the NF-kB 
p65 subunit. Reaction was quantified at 450 nm.
Quantification of apoptosis
Cell death detection ELISA kit (1544675, Ro-
che, Germany) was used to detect the cytosolic hi-
stone-associated DNA fragmentation, based on the 
manufacturer’s instructions. Cardiac cytoplasmic 
extracts (25 μL) were used as an antigen source in 
a sandwich ELISA. The data were reported as an 
apoptotic index (OD405/mg protein) to indicate the 
apoptosis rate.
Estimation of redox status  
in cardiac samples
Superoxide dismutase (SOD) and catalase 
activities, oxidized glutathione/reduced glutathione 
(GSSG/GSH) ratio and the levels of nitrite/nitra-
te and 8-isoprostane were estimated in cardiac 
cytoplasmic extracts using colorimetric assay 
kits (Cayman chem.) according to the procedures 
provided by the manufacturer and were calculated 
from plotted standard curves at 450 nm.
Insulin measurements
The plasma insulin concentration and the 
pancreatic insulin content were determined with 
rat ELISA kit (Cayman chem. 589501) according to 
the procedures provided by the manufacturer and 
were calculated from standard curves at 450 nm.
Data analysis
Data were expressed as the mean ± SE and 
were analyzed by repeated measure ANOVA for 
OGTT and one-way ANOVA for other parameters, 
using SPSS 21 software. When a significant p-value 
was obtained, the Tukey post-hoc test was employ-
ed to determine the differences between groups. 
A level of p < 0.05 was considered statistically 
significant.
Results
Morphology and insulin level
Table 1 shows that 4 months after diabetes 
induction, the diabetic rats in the DC and DTR 
groups show significant decline in the body weight 
compared to the NC group (p < 0.01 for both); 
However, this weight loss was lower in the DTR 
group than the DC group (p < 0.05). We did not see 
a significant difference between the body weights 
of the NTR and NC groups. On the other hand, the 
heart weight increased significantly in the DC and 
DTR groups when compared with the NC group 
(p < 0.05 for both), and 4 months’ resveratrol 
administration could not exert significant effect 
on this variable.
Table 1 represents also that the fasted plasma 
insulin concentration in both diabetic groups was 
significantly lower than in the NC group (p < 0.01 
for both) and resveratrol administration could not 
significantly change the insulin concentration in 
diabetic and non-diabetic rats. On the other hand, 
Figure 1. The results of oral glucose tolerance test at the 
end of protocol period (16th week). The values represent 
the mean ± SE of 12 animals per group; *p < 0.01 vs. 
normal control group (NC); #p < 0.05 vs. diabetic con-
trols (DC); $p < 0.05 vs. 60 min values; NTR — normal 
rats treated with resveratrol; DTR — diabetic rats trea-
ted with resveratrol.
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while the pancreatic insulin content in the DC 
and DTR groups was lower than in the NC group 
(p < 0.01 for both), four months treatment with 
resveratrol saved the pancreatic insulin content in 
the DTR group when compared with the DC group 
(p < 0.05) (Table 1). No significant difference was 
observed between the pancreatic insulin content 
of the NC and NTR groups.
OGTT
Figure 1 depicts the results of OGTT, perfor-
med at the end of the 16th week of the protocol. 
Although a significant hyperglycemia was observed 
at the baseline time (time 0) in both diabetic groups 
(p < 0.01 for both DC and DTR groups), the blood 
glucose concentration was lower in the DTR group 
than in the DC group (p < 0.05). While the blood 
glucose concentration in all groups increased to 
a maximum value at 60 min after glucose intake 
and decreased at 120 min, it did not revert to the 
baseline level in the DC and DTR groups. How-
ever, the blood glucose concentration in the DTR 
group at minute 120 was significantly lower than 
minute 60 values (p < 0.05). This indicates that 
the rate of peripheral glucose uptake was higher 
in the DTR group than in the DC group. We did 
not see a significant change in the blood glucose 
concentration between the NTR and NC groups.
Left ventricular pressures  
and coronary flow
Figure 2 depicts that in comparison to the 
NC group, LV diastolic pressure was higher in both 
diabetic groups (p < 0.01 for both) and resveratrol 
administration could not alleviate the elevated level 
in diabetic rats. Although LV developed pressure and 
coronary flow were lower in both diabetic groups 
than in the NC group (p < 0.01 for the DC and 
p < 0.05 for the DTR group), 4 months’ resveratrol 
administration markedly attenuated these abnorma-
lities in the DTR group as compared with the DC 
group (p < 0.05 for both comparisons). No significant 
differences were observed in the measured cardiac 
performance indices between the NTR and NC groups.
Redox status, NF-kB activity  
and apoptosis rate
Figure 3 represents the effect of chronic res-
veratrol administration on the cardiac oxidative 
markers (8-isoprostane, nitrite/nitrate and GSSG/ 
/GSH), antioxidant enzyme activities (SOD and 
catalase), NF-kB activity and apoptosis rate. In 
comparison to the normal control rats, treatment 
with resveratrol enhanced SOD activity and redu-
ced GSSG/GSH ratio in the heart of NTR group 
rats (p < 0.05 for both comparisons), while it has 
no significant effect on the other parameters. We 
observed reduced antioxidant enzymes activities 
Table 1. Effect of chronic resveratrol administration on the body weight, heart weight and fasted  
insulin levels in the blood and pancreas of experimental groups.
Body weight  
[g]
Heart weight  
[g]
Plasma insulin  
[pg/mL]
Pancreatic insulin  
[ng/mg protein]
NC 493.46 ± 25.16 0.92 ± 0.06 52.81 ± 7.95 3.07 ± 0.21
DC 241.28 ± 16.91* 1.42 ± 0.08** 15.42 ± 3.86* 1.12 ± 0.09*
NTR 481.71 ± 28.18 1.02 ± 0.05 48.61 ± 9.37 3.72 ± 0.37
DTR 301.14 ± 17.54*# 1.33 ± 0.06** 12.04 ± 5.29* 2.68 ± 0.26*# 
The values represent the mean ± SE of 12 animals per group; *p < 0.01 and **p < 0.05 vs. normal control group (NC), respectively;  
#p < 0.05 vs. diabetic control group (DC); NTR — normal rats treated with resveratrol; DTR — diabetic rats treated with resveratrol
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(p < 0.01 for SOD and p < 0.05 for catalase) with 
concomitant enhancement in nitrite/nitrate and 
8-isoprostane levels, GSSG/GSH ratio, NF-kB 
activity and apoptosis rate in the heart of the DC 
group (p < 0.01 for 8-isoprostane and NF-kB and 
p < 0.05 for the other parameters). All of these 
changes were significantly attenuated by chronic 
resveratrol administration (Fig. 3).
Figure 2. Effect of long-term treatment with resveratrol on the cardiac left ventricular diastolic pressure (A), left ven-
tricular developed (B) and coronary flow (C). The values represent the mean ± SE of 6 animals per group; *p < 0.01; 
**p < 0.05 vs. normal control group (NC); #p < 0.05 vs. diabetic control group (DC); NTR — normal rats treated with 
resveratrol, DTR — diabetic rats treated with resveratrol.
Figure 3. Effect of chronic resveratrol administration on the cardiac oxidative markers, apoptosis rate and the acti-
vity of antioxidant enzymes and NF-kB. The values represent the mean ± SE of 6 animals per group; *p < 0.01; 
**p < 0.05 vs. normal control group (NC); #p < 0.05 vs. diabetic control group (DC); NTR — normal rats treated with 
resveratrol; DTR — diabetic rats treated with resveratrol; SOD — superoxide dismutase; GSSG/GSH — oxidized to 
reduced glutathione ratio.
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Discussion
Blood glucose and body weight
Anti-hyperglycemic effect of resveratrol has 
been documented by several studies [5, 12, 13]. 
It is believed that resveratrol ameliorates dia-
betes-mediated hyperglycemia through insulin-
-dependent and insulin-independent pathways [5]. 
Szkudelski and Szkudelska [15] have reported that 
resveratrol preserves the pancreatic beta cells 
against chronic overstimulation leading to insulin 
secretion ability, at least for longer time. On the 
other hand, it has been shown that resveratrol 
increases the translocation of Glut-4 and glucose 
uptake in diabetic peripheral tissues through acti-
vation of some intracellular signaling components 
via an insulin-independent manner [8, 16]. In 
the present study, although resveratrol could not 
increase the blood insulin concentration in diabetic 
rats, it prevented from pancreatic insulin depletion 
and enhanced the peripheral glucose utilization. 
Improvement in glucose metabolism in turn pre-
vents from degradation of proteins and lipids from 
their reservoirs and attenuates the body weight 
loss during diabetes [11, 12, 17]. Improvement in 
insulin sensitivity after 4-week resveratrol admi-
nistration has been also recently reported in type 2 
diabetic patients, as well as in adults with impaired 
glucose tolerance [18, 19]. Moreover, Bhatt et al. 
[20] have shown that 3 months’ supplementation 
of resveratrol in type 2 diabetic patients improved 
glycemic control with no significant change in body 
weight. On the other hand, Poulsen et al. [21] have 
proved that 4 weeks’ treatment with resveratrol 
had no effect on resting energy expenditure and 
endogenous glucose turnover.
Diabetic heart and oxidative stress
During euglycemic condition, moderate 
amounts of reactive oxygen species (ROS) inclu-
ding superoxide (O2
•ˉ), hydrogen peroxide (H2O2), 
and hydroxyl radical (OH•) are produced in the cells 
and contribute to some physiological process. Dis-
mutation of O2
•ˉ to H2O2 by SOD, is the first step in 
ROS detoxification. Then, H2O2 is metabolized into 
water by the activities of catalase and glutathione 
peroxidase. Moreover, GSH, a co-substrate for 
glutathione peroxidase activity, is another major 
intra- and extracellular antioxidant molecule and 
acts as a direct free radical scavenger by conversion 
to GSSG [13]. GSSG to GSH ratio is a good marker 
for estimation of redox status [12, 22].
Chronic hyperglycemia results in oxidative 
stress through direct generation of ROS and re-
duction in the ability of the endogenous antioxi-
dants to neutralize ROS, and/or by altering the 
redox balance [23]. This situation is traceable 
by measurements of lipid peroxidation, protein 
oxidation, reduction of antioxidant enzymes acti-
vities and cell death [12]. Also, nitric oxide (NO•) 
can react with O2
•ˉ to form a potent oxidizing 
agent, peroxynitrite (ONOOˉ), and account for 
more cellular damage [12, 23]. Due to very low 
concentration and short half-life of NO•, its stable 
metabolites such as nitrite (NO2ˉ) and nitrate 
(NO3ˉ) are determined as suitable indices for 
estimation of NO• [24]. On the other hand, many 
of hyperglycemia-induced pathways converge to 
activate NF-kB, a proinflammatory master switch, 
which, in turn, contributes to increase of proinflam-
matory cytokine gene expressions, overproduction 
of NO•, oxidative stress worsening and apoptosis 
propelling in the heart [25].
In this context, our data are in agreement 
with the previous studies, in which our diabetic 
control rats experienced chronic hyperglycemia 
with reduction in SOD and catalase activity with 
concomitant enhancements in the cardiac oxidative 
stress markers (including 8-isoprostane, nitrite/
nitrate and GSSG /GSH ratio), NF-kB activity and 
apoptosis rate.
Resveratrol and cardioprotection
Antioxidant and cardioprotective properties 
of resveratrol have been documented by a variety 
of animal studies and human clinical trials [2, 5, 
26, 27]. In this context, it has been reported that 
resveratrol administration in patients with stable 
coronary artery disease (8–10 mg/kg for 3 and 
12 months), improved LV diastolic pressure and 
circulatory proinflammatory markers respectively 
[26, 27]. Also, Militaru et al. [28] have shown that 
60 days’ treatment with resveratrol decreased 
inflammatory markers in patients with stable an-
gina pectoris.
The beneficial effects of resveratrol with 
different dosage (2.5–20 mg/kg) in diabetic hearts 
have been previously reported by several animal 
studies and none of them have explored the effect 
of resveratrol for more than 2 months [5, 7, 9]. 
Thirunavukkarasu et al. [7] have shown that 15 days’ 
treatment with resveratrol (2.5 mg/kg/day) reduced 
cardiac apoptosis rate and improved LV developed 
pressure and coronary flow in diabetic rats through 
enhancement in NO∑ production and SOD activity. 
In addition, Zhang et al. [9] have demonstrated that 
resveratrol administration for 4 weeks (20 mg/kg/ 
/day) improved LV diastolic relaxation by stabili-
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zation of redox status and inhibiting the activity 
of NF-kB. In a recent study, Turan et al. [5] have 
shown that resveratrol given at 2.5 mg/kg/day 
orally for 4 weeks improved coronary perfusion 
pressure and heart rate in diabetic rats through 
reducing soluble sulfhydryl, nitrite and thioredoxin 
reductase levels and improvement in redox status. 
To the best of our knowledge, there is no published 
paper on the role of resveratrol in patients with 
diabetic cardiomyopathy.
The antioxidant property of resveratrol has 
been suggested to be performed directly by its 
free radical quenching action and by modulating 
the activation of NF-kB, proinflammatory mediators 
and antioxidant enzymes at transcriptional or post-
-transcriptional levels, or indirectly by reducing 
hyperglycemia [9, 16, 29–31].
In this context, our data are in accordance with 
the results from literature obtained from short-term 
resveratrol administration in diabetic hearts in which 
4-month oral resveratrol intake (5 mg/kg/day; orally) 
increased SOD and catalase activity, reduced oxidati-
ve stress markers (8-isoprostane, nitrite/nitrate and 
GSSG/GSH ratio), NF-kB activity and apoptosis rates 
in diabetic rats. Moreover, we showed that resvera-
trol improved LV developed pressure and coronary 
flow, but it could not affect the LV diastolic pressure 
significantly. While abnormal diastolic function is 
recognized as the earliest manifestation of diabetic 
cardiomyopathy, it is believed that the appearance of 
systolic dysfunction depends on duration of diabetes 
[1]. Hence, it is expectable that because of the long-
-term duration of uncontrolled diabetes in the present 
study, the diastolic dysfunction might be irreversible 
by resveratrol treatment.
Conclusions
In conclusion, our results depict that chronic 
resveratrol administration has an anti-hyperglyce-
mic effect in diabetic rats. Moreover, it alleviates 
the impairment of cardiac performance in part by 
reducing oxidative stress and apoptosis rate. While 
there is sufficient evidence from intact organ and 
animal studies to support the cardioprotective role 
of resveratrol in different forms of heart diseases, 
there are very few papers published on the effects of 
resveratrol on human heart and none of them have 
investigated its role on diabetic cardiomyopathy. 
Our observations may suggest that therapies du-
ring early stages of diabetes with antioxidant and 
anti-hyperglycemic agents such as resveratrol can 
potentially delay or attenuate the progression of 
diabetic cardiomyopathy but further human clinical 
trials are needed to confirm this hypothesis.
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